Haifa, Israel

Zahava Vadasz

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 49(Granted Patents)


Company Filing History:


Years Active: 2012-2020

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Zahava Vadasz: Innovator in Medical Research

Introduction

Zahava Vadasz is a prominent inventor based in Haifa, Israel. She has made significant contributions to the field of medical research, particularly in the treatment and assessment of inflammatory bowel disease and asthma. With a total of 7 patents to her name, her work has the potential to impact many lives.

Latest Patents

Among her latest patents, Zahava Vadasz has developed methods involving Semaphorin 3A for the treatment and assessment of the severity of inflammatory bowel disease (IBD). This invention provides a means to assess IBD severity or treatment efficacy by determining Semaphorin 3A levels in biological samples from affected individuals. Additionally, she has created methods for treating asthma using Semaphorin 3A, which also includes assessing asthma severity or treatment efficacy through the measurement of Semaphorin 3A levels in biological samples.

Career Highlights

Zahava Vadasz has worked with notable organizations such as the Technion Research & Development Foundation Limited and the Medical Research & Development Fund for Health Services at Bnai Zion Medical Center. Her work in these institutions has allowed her to advance her research and contribute to significant medical advancements.

Collaborations

Zahava has collaborated with esteemed colleagues, including Elias Toubi and Gera Neufeld. These partnerships have further enriched her research and innovation in the medical field.

Conclusion

Zahava Vadasz stands out as an influential inventor in medical research, with her innovative patents addressing critical health issues. Her contributions continue to pave the way for advancements in treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…